Arbutus Biopharma Corp ABUS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$4.19 up $0.08, 1.95% at close Oct 14
Last close · Previous close $4.11
- Market cap
- At the Oct 14 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- Last 12 months
Price chart
$4.19up $0.08, 1.95%Wed, Oct 14 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$4.11Oct 13
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Valuation
Financials
Dividends
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus’ pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ABUS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ABUS stock FAQ
What is ABUS stock’s price today?
Arbutus Biopharma (ABUS) traded at $4.19 at the close on , up $0.08 (1.95%) from the previous close of $4.11.
What exchange does ABUS trade on?
Arbutus Biopharma trades on the Nasdaq under the ticker symbol ABUS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.